- Home
- MBRX
as 11-15-2024 4:00pm EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 7.7M | IPO Year: | 2016 |
| Target Price: | $31.00 | AVG Volume (30 days): | 54.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $6.24 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
TipRanks
5 days ago
Moleculin Biotech Reports Financial Highlights and Future Plans
PR Newswire
6 days ago
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Thomson Reuters StreetEvents
6 days ago
Q3 2024 Moleculin Biotech Inc Earnings Call
PR Newswire
7 days ago
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
13 days ago
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
PR Newswire
14 days ago
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
TipRanks
a month ago
Moleculin Biotech Highlights Annamycin’s AML Treatment Potential
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.